Seattle Genetics Inc. (SGEN)
SGEN (NASDAQ:Drugs)
$36.13
+0.40
+1.12%
Today's Range: 35.72 - 36.43 |
SGEN Avg Daily Volume: 808,400
| Last Update: 05/22/13 - 1:15 PM EDT |
| Volume: 363,953 |
| YTD Performance: 54.29%
|
| Open: $35.76 |
| Previous Close: $35.73 |
| 52 Week Range: $19.03 -
$39.00 |
| Oustanding Shares: 121,265,608 |
| Market Cap: 4,335,245,486 |
6-Month Chart
TheStreet Ratings Grade for SGEN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
3 |
3 |
3 |
3 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
5 |
5 |
5 |
5 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
2 |
2 |
2 |
2 |
| Mean Rec. |
2.73 |
2.73 |
2.73 |
2.73 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
-72.96 |
|
| Price Earnings Comparisons: |
| SGEN |
Sector Avg. |
S&P 500 |
| -72.96 |
0.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
30.19%
|
78.12%
|
191.12%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
122.40 |
3.06 |
0.59 |
| Net Income |
0.00 |
-0.34 |
0.00 |
| EPS |
0.00 |
-0.49 |
0.00 |
| Earnings for SGEN: |
| EBITDA |
-0.05B |
| Revenue |
0.21B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.18 |
$-0.24 |
$-0.82 |
$-0.51 |
| Number of Analysts |
9 |
9 |
10 |
9 |
| High Estimate |
$0.04 |
$-0.19 |
$-0.72 |
$0.25 |
| Low Estimate |
$-0.26 |
$-0.34 |
$-0.93 |
$-0.88 |
| Prior Year |
$-0.15 |
$-0.12 |
$-0.46 |
$-0.82 |
| Growth Rate (Year over Year) |
-22.22% |
-98.15% |
-77.17% |
37.56% |
| May 08, 2013 | 10:18 AM EDT
Here is my compilation of last night's profit reports.
Feb 13, 2013 | 7:23 AM EST
SGEN was downgraded from Buy to Hold, Needham said. Adcetris sales are lagging expectations.
Nov 13, 2012 | 7:17 AM EST
SGEN was initiated with an Outperform rating, Credit Suisse said. $28 price target. Company is a market leader and can continue to grow...
Nov 08, 2012 | 7:02 AM EST
SGEN was downgraded from Hold to Sell, Cantor FItzgerald said. $20 price target. Adcetris is growing slower than expected.
...
Sep 07, 2012 | 9:08 AM EDT
Shares of SGEN downgraded to Perform from Outperform, Oppenheimer said. $27 price target. Valuation call.
Aug 21, 2012 | 6:17 AM EDT
SGEN was initiated with a Buy rating, Cantor Fitzgerald said. $30 price target. New data should ultimately lead to more indications for...
Jul 05, 2012 | 8:13 AM EDT
SGEN was initiated with a Buy rating, Think Equity said. $30 price target. Adcetris opportunity in Hodgkin's lymphoma.
By
Adam Feuerstein and Gregg Greenberg
Apr 27, 2012 | 5:00 AM EDT
Adam Feuerstein, Sr. Columnist for TheStreet, says M&A is the next big thing in biotech.
By
Adam Feuerstein and Gregg Greenberg
Jan 06, 2012 | 5:15 AM EST
Adam Feuerstein, Sr. Columnist for TheStreet, previews next week's JP Morgan Healthcare Conference and also looks ahead to 2012.
